Article

barrons.com on 2022-01-07 21:47

Biogen’s Alzheimer’s Drug Has Another Shot at Success3 min read

Biogen investors are eagerly awaiting guidance about whether and how Medicare will cover the drugmaker’s Alzheimer’s disease therapy, Aduhelm.

Related news